No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SDZNY Sandoz Group AG
- 36.200
- -0.370-1.01%
15min DelayClose Jun 28 16:00 ET
15.56BMarket Cap201.11P/E (TTM)
36.330High36.040Low36.19KVolume36.090Open36.570Pre Close1.31MTurnover0.01%Turnover Ratio201.11P/E (Static)429.93MShares37.12052wk High1.80P/B15.56BFloat Cap25.33552wk Low--Dividend TTM429.93MShs Float37.120Historical High--Div YieldTTM0.79%Amplitude25.335Historical Low36.166Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
U.S. Drug Shortages Worsen to Reach a Decade High: Report
Sandoz Receives European Commission Approval for Wyost and Jubbonti, the First and Only Biosimilars of Denosumab in Europe
Individual Investors Who Own 60% Along With Institutions Invested in Sandoz Group AG (VTX:SDZ) Saw Increase in Their Holdings Value Last Week
Express News | Sandoz Q1 Sales $2.492B Up From $2.384B YoY
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg